Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Sep 29:15:2077-2086.
doi: 10.2147/CCID.S379323. eCollection 2022.

An Autologous Topical Serum Derived from Platelet-Rich Plasma Therapy for the Management of Sensitive Skin Alterations: A Case Series Report

Cristina García-Millan  1 , Ander Pino  2 , Rita Rodrigues  1 , Gonzalo Segurado-Miravalles  1   3 , Adrián Alegre-Sánchez  1 , Pedro Jaén  1   3 , Eduardo Anitua  2
Affiliations
Case Reports

An Autologous Topical Serum Derived from Platelet-Rich Plasma Therapy for the Management of Sensitive Skin Alterations: A Case Series Report

Cristina García-Millan et al. Clin Cosmet Investig Dermatol. .

Abstract

Background: Although the underlying pathophysiology of sensitive skin remains unknown, it presents clinical symptoms like erythema, burning and dryness associated with other inflammatory dermatoses such as dermatitis or rosacea.

Objective: The aim of the present report was to provide preliminary data about the efficacy of Endoret-Serum (ES) as an autologous therapy for the topical management of sensitive skin alterations.

Materials and methods: Five patients underwent a daily topical ES treatment that was maintained for three months. Clinical assessment was carried out using validated dermatological surveys (DLQI, IGA, Likert, PGI-I). Additionally, skin hydration measurement and high-resolution topographic and reflectance confocal imaging analysis were carried out.

Results: No adverse events were observed during the treatment. At the end of the follow-up period, surveys highlighted a significant therapeutic effect compared to baseline. Skin hydration was also improved, and topographic images showed a decrease in patient's underlying inflammatory and vascular condition.

Conclusion: This preliminary report suggests that Endoret-Serum may be useful in the management of clinical symptoms derived from sensitive skin alterations.

Keywords: case report; growth factors; platelet-rich plasma; sensitive skin; topical formulation.

PubMed Disclaimer

Conflict of interest statement

Eduardo Anitua is the scientific director and Ander Pino is researcher at BTI Biotechnology Institute, the company that has developed the Endoret®PRGF® technology. The rest of the authors declare no conflict of interest. No funding was received for this study.

Figures

Figure 1
Figure 1
(A) Representative image of ES application onto cutaneous tissue. (B) ES drop after extrusion onto cutaneous surface. (C) ES spreading over the skin. (D) ES integration within the epidermal layer.
Figure 2
Figure 2
(A) Dermatology Life Quality Index (DLQI) of patients during the study showed a reduction of 7-fold and 13-fold after one and three months of ES treatment respectively. (B) Cutaneous hydration results revealed an increase after one and three months of ES therapy.
Figure 3
Figure 3
(A) In some patients, cutaneous in vivo reflectance confocal microscopy (RCM) evaluation showed a decrease in dermal inflammatory infiltrate (white dots) when comparing baseline (up) and post-treatment images (down). (B) Self-assessment questionnaires showed that patients referred to be very satisfied with ES and noticed a much better condition when comparing to their baseline status. Healthcare specialists also observed minimal dermatological symptoms at the end of the treatment.
Figure 4
Figure 4
Topographic skin complexion analysis using the Reveal imaging system. Cross polarized (A, B, E and F) and RBX Red (C, D, G and H) images are displayed. Patients presented noticeable improvement in the underlying vascular condition after ES therapy.
Figure 5
Figure 5
Topographic skin complexion analysis using the Reveal imaging system. Cross polarized (A, B, E and F) and RBX Brown (C, D, G and H) images are displayed. Patients presented slight reduction in hyperpigmented spots after ES therapy.
See this image and copyright information in PMC

References

    1. Misery L. Sensitive skin. Expert Rev Dermatol. 2013;8(6):631–637. doi: 10.1586/17469872.2013.856688 - DOI
    1. Farage MA, Maibach HI. Sensitive skin: closing in on a physiological cause. Contact Dermatitis. 2010;62(3):137–149. doi: 10.1111/j.1600-0536.2009.01697.x - DOI - PubMed
    1. Farage M. How do perceptions of sensitive skin differ at different anatomical sites? An epidemiological study. Clin Exp Dermatol. 2009;34(8):e521–e30. doi: 10.1111/j.1365-2230.2009.03487.x - DOI - PubMed
    1. Lev-Tov H, Maibach HI. The sensitive skin syndrome. Indian J Dermatol. 2012;57(6):419. doi: 10.4103/0019-5154.103059 - DOI - PMC - PubMed
    1. Misery L, Boussetta S, Nocera T, Perez‐Cullell N, Taieb C. Sensitive skin in Europe. J Eur Acad Dermatol Venereol. 2009;23(4):376–381. doi: 10.1111/j.1468-3083.2008.03037.x - DOI - PubMed

Publication types